Related Experiment Videos
Response to pneumococcal vaccine among children with Hodgkin's disease
Insights
Pneumococcal vaccination in children with Hodgkin's disease is more effective before splenectomy. Post-treatment immunization yields a reduced antibody response, highlighting the need for careful timing of vaccines in immunocompromised patients.
Area of Science:
- Immunology
- Pediatric Oncology
Background:
- Children with Hodgkin's disease often undergo splenectomy, irradiation, and chemotherapy, compromising their immune function.
- Pneumococcal infections pose a significant risk to asplenic individuals, particularly those undergoing cancer treatment.
Purpose of the Study:
- To evaluate the efficacy and duration of antibody response to pneumococcal vaccination in children with Hodgkin's disease.
- To determine the impact of splenectomy, irradiation, and chemotherapy timing on vaccine immunogenicity.
Main Methods:
- Nineteen children with Hodgkin's disease received a dodecavalent pneumococcal vaccine.
- Sera were analyzed for antibody levels against 12 pneumococcal serotypes.
- Immunization timing relative to splenectomy and adjuvant therapy (irradiation and MOPP chemotherapy) was compared.
Main Results:
- Children immunized before splenectomy showed a significantly higher antibody response (67% of antigens) compared to those immunized after treatment (40% of antigens) (P < 0.0001).
- The duration of antibody response was variable.
- Response to one pneumococcal antigen did not guarantee response to others.
Conclusions:
- Pneumococcal vaccination is more immunogenic when administered before splenectomy in children with Hodgkin's disease.
- The timing of immunization is crucial for optimizing vaccine efficacy in this patient population.
- Reliance solely on pneumococcal vaccine for infection prevention in asplenic children with Hodgkin's disease is not advisable due to variable responses.
Abstract:
Nineteen children with Hodgkin's disease were immuized with dodecavalent pneumococcal vaccine; the efficacy of vaccination, the duration of response, and the significance of the time of immunization in relation to splenectomy and subsequent irradiation and chemotherapy were investigated. Eight children were immunized before splenectomy, and 11 were immunized after splenectomy, irradiation, and chemotherapy. All children were irradiated, and all but two received chemotherapy with MOPP (nitrogen mustard, vincristine sulfate, procarbazine, and prednisone). Sera were assayed for antibodies to the 12 polysaccharide types in the vaccine. The group of children immunized before splenectomy had a significant antibody response to 67% of the antigens tested, whereas the group immunized after splenectomy responded to 40% of the antigens (P less than 0.0001). The duration of response was variable. Pneumococcal vaccine was more likely to provoke an immunologic response if administered before splenectomy than if administered after splenectomy, irradiation, and chemotherapy; however, the response was not uniform. A response to one antigen did not necessarily imply a response to other antigens. In the absence of a readily available assay to determine a protective antibody response, one cannot rely on the vaccine as the sole means of preventing pneumococcal infections in asplenic children with Hodgkin's disease.